Abstract: A directly compressible composition includes more than 30% by weight of allulose. The directly compressible composition can form tablets. A method for the manufacture of allulose granules includes: a step (a) of preparing a granulation liquid comprising allulose; a step (b) of granulating powdery allulose, by applying the granulation liquid obtained in step (a) onto moving powdery allulose; a step (c), simultaneous with step (b), of drying the granules obtained in step (b); a step (c?) of maturation of the granules obtained in step (c); and a step (d) of recovering the granules obtained in step (c) or (c?).

Abstract: Disclosed is a process for preparing an encapsulated fragrance composition. The composition comprises a plurality of microcapsules dispersed in a dispersion medium. The microcapsules comprise a core and a shell around the core. The process comprises the consecutive steps of: a) Providing an aqueous phase (I) comprising at least one anionically modified polyisocyanate (A); b) Providing an organic phase (II) comprising at least one fragrance ingredient; c) Mixing the aqueous phase (I) and the an organic phase (II) to obtain a mixture; d) Forming an emulsion comprising droplets of the organic phase (II) in the continuous aqueous phase (I); e) Adding at least one polyfunctional amine; f) Effecting formation of shells around the droplets formed in step d), to obtain a dispersion of microcapsules. The process comprises the additional step of adding a polyisocyanate (B), which is different from polyisocyanate (A).

Abstract: The present invention discloses a method for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants, using one or plant actives selected from group comprising a composition comprising not less than 10% w/w oroxylin A, not less than 10% w/w baicalein and not less than 2% w/w chrysin; 95% w/w oxyresveratrol; 95% w/w tetrahydrocurcumin; 90% w/w pterostilbene and a composition comprising at least 10% w/w ?-glucogallin and at least 10% w/w total mucic acid gallates. The invention also discloses a method for cleansing and rejuvenating mammalian skin, exposed to environmental pollutants and UV radiation using the aforesaid plant actives.

Abstract: Cleavable surfactants of formula (I) having a total hydrophilic-lipophilic balance (HLB) of between 3 and 18 and wherein A is a group capable of releasing a flavor or fragrance aldehyde of formula (R1)CHO or a flavor or fragrance ketone of formula (R1)(R2)CO and is of formula wherein the wavy line indicates the location of the bond between L and A; R1 and R2 represent a hydrogen atom or a saturated or unsaturated C1-C18 hydrocarbon group, provided that at least one of the R1 or R2 groups has 6 consecutive carbon atoms and that both R1 and R2 taken together comprise a maximum of 18 carbon atoms; and L is a linear, branched or cyclic, saturated or unsaturated C3 to C40 hydrocarbon group. These surfactants solubilize and/or stabilize flavor and fragrance aldehydes and ketones in an aqueous environment and at the same time to control their release by hydrolysis.

Abstract: Polyurea capsules that encapsulate active materials in polymeric walls resulting from the polymerization of an aromatic or aliphatic polyisocyanate and a cross-linking agent are provided as are consumer products containing said polyurea capsules and for methods for producing such capsules.

Abstract: The present invention provides lignin nanoparticles containing a hydrophobic active agent and a process for the production of the lignin nanoparticles. The process involves the following steps: (i) dissolving modified lignin and a hydrophobic active agent in an organic solvent having low solubility in water; (ii) combining the solution with water and a surfactant to form a pre-emulsion; (iii) forming an emulsion from the pre-emulsion; and (iv) crosslinking the modified lignin to form the lignin nanoparticles, in which the modified lignin is lignin which is chemically modified to contain at least two functional groups suitable for polymerization and/or crosslinking.

Abstract: Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.

Abstract: To provide a cosmetic which is environmentally friendly and is excellent in all of spreadability on application, adhesion, hand feeling properties and transparency. A cosmetic including aliphatic polyester-based resin particles, wherein the aliphatic polyester-based resin particles have a volume-average particle diameter of 2 to 30 ?m, and a ratio of particles having a particle diameter of less than 1 ?m is 15% by volume or less and a ratio of particles having a particle diameter of more than 30 ?m is 6% by volume or less, is provided.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

Abstract: Provided is a novel additive for an orally disintegrating tablet providing quick disintegrability and tablet hardness to the orally disintegrating tablet, and a producing method therefor. According to an embodiment of the present invention, there is provided an additive for an orally disintegrating tablet characterized by including D-mannitol, low-substituted hydroxypropyl cellulose (however, excluding the low-substituted hydroxypropyl cellulose having a mean particle size of 20 ?m or less and a substitution degree of hydroxypropoxy groups of 11%, a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 14%, and a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 11% and a 90% cumulated particle size of 100 ?m or less), crospovidone, and microcrystalline cellulose, wherein the low-substituted hydroxypropyl cellulose and the crospovidone are included in a ratio of 5:4.

Abstract: Disclosed herein are methods and compositions for treating, inhibiting, or ameliorating pulmonary infections, including cystic fibrosis. Aspects described herein relate to compositions including a saline solution and hypochlorite and methods of using these compositions alone or in combination with additional compounds, including antibiotics, an anti-inflammatories, bronchodilators, mucolytics, or oxygen therapy for treating, ameliorating, or inhibiting a pulmonary infection, including cystic fibrosis.

Abstract: The present invention relates to an aqueous composition for ophthalmological use or otolaryngological use, the aqueous composition containing: (A) a petrolatum; and two or more (B) nonionic surfactants.

Abstract: Provided are solid dispersions of Compound I having the formula: wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Abstract: A synthetic nicotine composition comprising synthetic nicotine, a synthetic nicotine salt and a synthetic nicotine derivative, wherein the synthetic nicotine, the synthetic nicotine salt, and the synthetic nicotine derivative are in mass percentage; the synthetic nicotine accounts for 1-20%, the synthetic nicotine salt accounts for 30-70%, and the synthetic nicotine derivative accounts for 20-50%; and the synthetic nicotine is one or more of S-nicotine and a mixture of R-nicotine containing a racemate and S-nicotine.

Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

Abstract: An embodiment includes a system comprising a thermoset polyurethane shape memory polymer (SMP) foam that includes at least one antimicrobial agent. The antimicrobial agent may include at least one phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the SMP foam. Other embodiments are described herein.

Abstract: A medical hydrogel composition, a medical hydrogel, a preparation method therefore and an application thereof, and a medical hydrogel kit. The medical hydrogel composition comprises a first component and a second component; the first component comprises polylysine and polyethylene imine; the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, and 4-arm-polyethylene glycol-succinimidyl carbonate; the degree of polymerization of the polylysine is 20 or more. The medical hydrogel is formed by reacting the first component with the second component of the medical hydrogel composition. The medical hydrogel kit comprises the medical hydrogel composition and a buffer solution used for dissolving the components of the medical hydrogel composition. The medical hydrogel has a degree of swelling of ?10%-50%, and can be applied in narrow parts where cranial, spinal, and peripheral nerves are densely distributed.

Abstract: The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with ?-amyloid deposition, preferably AD.